Literature DB >> 9561378

Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases.

C Agostoni1, N Dorigoni, A Malfitano, L Caggese, G Marchetti, S Corona, S Gatti, M Scaglia.   

Abstract

Twenty-two Italian HIV-infected patients developed leishmaniasis, clinically manifested as visceral (13 cases), cutaneous (2 cases) and disseminated disease (7 cases). Twenty were males and two females (mean age: 32.8 years) with a mean CD4+ cell count of 46.8/microliter at diagnosis; risk factors were intravenous drug use (17 patients) and sexual behaviour (two bisexual, two homosexual, one heterosexual). All but one patient lived or travelled in hypoendemic Italian regions and other Mediterranean countries. Apart from the two patients with cutaneous leishmaniasis, the clinico-pathological and biological spectrum of the infection was often atypical, especially in patients with disseminated disease. The diagnosis was routinely made by direct recovery of parasites in biological specimens, mainly in bone marrow aspirate, whereas serology was negative or borderline in most of the patients. Among 17 in vitro isolates, Leishmania infantum was the only species involved with previously undescribed isoenzyme patterns in two cases. Treatment with antimonials and other drugs showed only temporary clinical improvement in some patients. Relapses were the rule. Leishmaniasis confirms itself as an opportunistic infection in HIV-positive persons. Secondary chemoprophylaxis should be considered in cases of relapsing disease.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Cross Sectional Analysis; Developed Countries; Diseases; Europe; Hiv Infections; Italy; Leishmaniasis; Mediterranean Countries; Parasitic Diseases; Research Methodology; Research Report; Signs And Symptoms; Southern Europe; Viral Diseases

Mesh:

Year:  1998        PMID: 9561378     DOI: 10.1007/BF02767767

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

1.  Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients.

Authors:  J A Pérez-Molina; R López-Vélez; P Montilla; A Guerrero
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

2.  Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals.

Authors:  J A Pérez-Molina; A Guerrero
Journal:  Am J Med       Date:  1997-01       Impact factor: 4.965

3.  Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1997-02-21

Review 4.  Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.

Authors:  J D Berman
Journal:  Clin Infect Dis       Date:  1997-04       Impact factor: 9.079

Review 5.  Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy.

Authors:  B S Peters; D Fish; R Golden; D A Evans; A D Bryceson; A J Pinching
Journal:  Q J Med       Date:  1990-11

6.  Leishmaniasis and AIDS co-infection: the Spanish example.

Authors:  J Alvar
Journal:  Parasitol Today       Date:  1994-04

7.  Leishmania and the pathogenesis of HIV infection.

Authors:  M Tremblay; M Olivier; R Bernier
Journal:  Parasitol Today       Date:  1996-07

8.  HIV-Leishmania co-infections in Italy. Isoenzyme characterization of Leishmania causing visceral leishmaniasis in HIV patients.

Authors:  M Gramiccia; L Gradoni; M Troiani
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Mar-Apr       Impact factor: 2.184

9.  Visceral leishmaniasis and HIV-1 co-infection in southern France.

Authors:  E Rosenthal; P Marty; I Poizot-Martin; J Reynes; F Pratlong; A Lafeuillade; D Jaubert; O Boulat; J Dereure; F Gambarelli
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Mar-Apr       Impact factor: 2.184

10.  Treatment of Mediterranean visceral leishmaniasis.

Authors:  L Gradoni; A Bryceson; P Desjeux
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

View more
  4 in total

1.  Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia.

Authors:  Tesfaye Gelanew; Zewdu Hurissa; Ermias Diro; Aysheshm Kassahun; Katrin Kuhls; Gabriele Schönian; Asrat Hailu
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Authors:  A Campos-Neto; J R Webb; K Greeson; R N Coler; Y A W Skeiky; S G Reed
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 3.  Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.

Authors:  Gláucia F Cota; Marcos R de Sousa; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2011-06-07

4.  Changing demographics of visceral leishmaniasis in northeast Brazil: Lessons for the future.

Authors:  Iraci Duarte Lima; Adila L M Lima; Carolina de Oliveira Mendes-Aguiar; José F V Coutinho; Mary E Wilson; Richard D Pearson; José Wilton Queiroz; Selma M B Jeronimo
Journal:  PLoS Negl Trop Dis       Date:  2018-03-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.